Overview

* MediPharm Labs Q3 2025 revenue grows 17% yr/yr

* Operating expenses decreased 19% yr/yr, contributing to increased cash balance

Outlook

* MediPharm ( MEDIF ) plans to launch inhalers in international markets, including the UK

* Company focuses on international medical cannabis market expansion

* MediPharm ( MEDIF ) aims to enhance profitability by streamlining expenses

Result Drivers

* INTERNATIONAL SALES - 83% yr/yr growth in international medical cannabis revenue, now 56% of total revenue

* COST MANAGEMENT - Operating expenses decreased 19% yr/yr, contributing to increased cash balance

* PRODUCT EXPANSION - Expanded inhaler line in domestic market and launched metered dose inhalers in Australia

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss C$11.40 C$11.90

Revenue mln mln (1

Analyst)

Q3 Miss -C$1.10 C$443,00

Adjusted mln 0 (1

EBITDA Analyst)

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)